Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide.
FAIL · Does not pass the screen
6.07 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 13 days ago
Screened 2026-10-23 · the tape above runs as of 14:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price6.07 USD at the 23 Oct 2026 close
Fair valueUnder review: its inputs are 13 days old; there is no analyst estimate to cross-check it.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price6.07 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Markup6.07+0.0% to today ✓Accumulation gives way to Markup after a 7% rise in 4 weeks
2026-10-02Read Accumulation5.65+7.4% to today ✓Markdown gives way to Accumulation
2026-09-15Read Markdown5.51+10.2% to today Markup gives way to Markdown after a 16% slide in 11 weeks
2026-07-02Read Markup6.58-7.8% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ultralife Corp holds its Markup at $6.07. The statistical read favours the sellers, held for 34 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 34 days
Price at the screen
$6.07
Valuation
N/A trailing · 6.28 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.78
The Workings
Five Screens, Shown in Full
Does not pass. Business activity: leveraged / inverse / derivative instrument (gharar)
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Its core business involves an activity the values screen does not clear.
Fail
Debt load
22.89%
Below 33%
Interest-bearing debt is just 22.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
19.96%
Below 49%
Money owed to the company is 20.0% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ultralife does not clear the screen at the business-activity stage. It operates in an area the screen excludes: leveraged / inverse / derivative instrument (gharar), so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ULBI's ethical verdict changes
Today ULBI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 13 days old; there is no analyst estimate to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ULBI trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup · changed$6.07+0.3%Entry 8
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
2026-10-23Accumulation$6.05+7.1%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
2026-10-02Accumulation · changed$5.65+2.5%Entry 6
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
2026-09-15Markdown · changed$5.51+0.0%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
2026-08-15Markup$5.51-16.3%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 16.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
2026-07-18Markup$6.58+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
2026-07-03Markup$6.58+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$6.58Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.